Antiretroviral resistance during successful therapy of HIV type 1 infection

J. Martinez-Picado; M. P. DePasquale; N. Kartsonis; G. J. Hanna; J. Wong; D. Finzi; E. Rosenberg; H. F. Günthard; L. Sutton; A. Savara; C. J. Petropoulos; N. Hellmann; B. D. Walker; D. D. Richman; R. Siliciano; R. T. D'Aquila

doi:10.1073/pnas.97.20.10948

Antiretroviral resistance during successful therapy of HIV type 1 infection

J. Martinez-Picado, M. P. DePasquale, N. Kartsonis, G. J. Hanna, J. Wong, D. Finzi, E. Rosenberg, H. F. Günthard, L. Sutton, A. Savara, C. J. Petropoulos, N. Hellmann, B. D. Walker, D. D. Richman, R. Siliciano, R. T. D'Aquila

Howard Hughes Medical Institution

Research output: Contribution to journal › Article › peer-review

192 Scopus citations

Abstract

HIV type 1 (HIV-1) drug resistance mutations were selected during antiretroviral therapy successfully suppressing plasma HIV-1 RNA to <50 copies/ml. New resistant mutant subpopulations were identified by clonal sequencing analyses of viruses cultured from blood cells. Drug susceptibility tests showed that biological clones of virus with the mutations acquired during successful therapy had increased resistance. Each of the five subjects with new resistant mutants had evidence of some residual virus replication during highly active antiretroviral therapy (HAART), based on transient episodes of plasma HIV-1 RNA > 50 copies/ml and virus env gene sequence changes. Each had received a suboptimal regimen before starting HAART. Antiretroviral-resistant HIV-1 can be selected from residual virus replication during HAART in the absence of sustained rebound of plasma HIV-1 RNA.

Original language	English (US)
Pages (from-to)	10948-10953
Number of pages	6
Journal	Proceedings of the National Academy of Sciences of the United States of America
Volume	97
Issue number	20
DOIs	https://doi.org/10.1073/pnas.97.20.10948
State	Published - Sep 26 2000

ASJC Scopus subject areas

General

Access to Document

10.1073/pnas.97.20.10948

Cite this

Martinez-Picado, J., DePasquale, M. P., Kartsonis, N., Hanna, G. J., Wong, J., Finzi, D., Rosenberg, E., Günthard, H. F., Sutton, L., Savara, A., Petropoulos, C. J., Hellmann, N., Walker, B. D., Richman, D. D., Siliciano, R., & D'Aquila, R. T. (2000). Antiretroviral resistance during successful therapy of HIV type 1 infection. Proceedings of the National Academy of Sciences of the United States of America, 97(20), 10948-10953. https://doi.org/10.1073/pnas.97.20.10948

Martinez-Picado, J, DePasquale, MP, Kartsonis, N, Hanna, GJ, Wong, J, Finzi, D, Rosenberg, E, Günthard, HF, Sutton, L, Savara, A, Petropoulos, CJ, Hellmann, N, Walker, BD, Richman, DD, Siliciano, R & D'Aquila, RT 2000, 'Antiretroviral resistance during successful therapy of HIV type 1 infection', Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 20, pp. 10948-10953. https://doi.org/10.1073/pnas.97.20.10948

@article{3e7c92e70d364640873bf129f50b8df0,

title = "Antiretroviral resistance during successful therapy of HIV type 1 infection",

abstract = "HIV type 1 (HIV-1) drug resistance mutations were selected during antiretroviral therapy successfully suppressing plasma HIV-1 RNA to <50 copies/ml. New resistant mutant subpopulations were identified by clonal sequencing analyses of viruses cultured from blood cells. Drug susceptibility tests showed that biological clones of virus with the mutations acquired during successful therapy had increased resistance. Each of the five subjects with new resistant mutants had evidence of some residual virus replication during highly active antiretroviral therapy (HAART), based on transient episodes of plasma HIV-1 RNA > 50 copies/ml and virus env gene sequence changes. Each had received a suboptimal regimen before starting HAART. Antiretroviral-resistant HIV-1 can be selected from residual virus replication during HAART in the absence of sustained rebound of plasma HIV-1 RNA.",

author = "J. Martinez-Picado and DePasquale, {M. P.} and N. Kartsonis and Hanna, {G. J.} and J. Wong and D. Finzi and E. Rosenberg and G{\"u}nthard, {H. F.} and L. Sutton and A. Savara and Petropoulos, {C. J.} and N. Hellmann and Walker, {B. D.} and Richman, {D. D.} and R. Siliciano and D'Aquila, {R. T.}",

year = "2000",

month = sep,

day = "26",

doi = "10.1073/pnas.97.20.10948",

language = "English (US)",

volume = "97",

pages = "10948--10953",

journal = "Proceedings of the National Academy of Sciences of the United States of America",

issn = "0027-8424",

publisher = "National Academy of Sciences",

number = "20",

}

TY - JOUR

T1 - Antiretroviral resistance during successful therapy of HIV type 1 infection

AU - Martinez-Picado, J.

AU - DePasquale, M. P.

AU - Kartsonis, N.

AU - Hanna, G. J.

AU - Wong, J.

AU - Finzi, D.

AU - Rosenberg, E.

AU - Günthard, H. F.

AU - Sutton, L.

AU - Savara, A.

AU - Petropoulos, C. J.

AU - Hellmann, N.

AU - Walker, B. D.

AU - Richman, D. D.

AU - Siliciano, R.

AU - D'Aquila, R. T.

PY - 2000/9/26

Y1 - 2000/9/26

N2 - HIV type 1 (HIV-1) drug resistance mutations were selected during antiretroviral therapy successfully suppressing plasma HIV-1 RNA to <50 copies/ml. New resistant mutant subpopulations were identified by clonal sequencing analyses of viruses cultured from blood cells. Drug susceptibility tests showed that biological clones of virus with the mutations acquired during successful therapy had increased resistance. Each of the five subjects with new resistant mutants had evidence of some residual virus replication during highly active antiretroviral therapy (HAART), based on transient episodes of plasma HIV-1 RNA > 50 copies/ml and virus env gene sequence changes. Each had received a suboptimal regimen before starting HAART. Antiretroviral-resistant HIV-1 can be selected from residual virus replication during HAART in the absence of sustained rebound of plasma HIV-1 RNA.

AB - HIV type 1 (HIV-1) drug resistance mutations were selected during antiretroviral therapy successfully suppressing plasma HIV-1 RNA to <50 copies/ml. New resistant mutant subpopulations were identified by clonal sequencing analyses of viruses cultured from blood cells. Drug susceptibility tests showed that biological clones of virus with the mutations acquired during successful therapy had increased resistance. Each of the five subjects with new resistant mutants had evidence of some residual virus replication during highly active antiretroviral therapy (HAART), based on transient episodes of plasma HIV-1 RNA > 50 copies/ml and virus env gene sequence changes. Each had received a suboptimal regimen before starting HAART. Antiretroviral-resistant HIV-1 can be selected from residual virus replication during HAART in the absence of sustained rebound of plasma HIV-1 RNA.

UR - http://www.scopus.com/inward/record.url?scp=12944335238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12944335238&partnerID=8YFLogxK

U2 - 10.1073/pnas.97.20.10948

DO - 10.1073/pnas.97.20.10948

M3 - Article

C2 - 11005867

AN - SCOPUS:12944335238

SN - 0027-8424

VL - 97

SP - 10948

EP - 10953

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

IS - 20

ER -

Antiretroviral resistance during successful therapy of HIV type 1 infection

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this